Skip to main content Back to Top


Vitamin K (Phytonadione) Injection

Reason for the Shortage

    • Pfizer had vitamin K injection on market reserve due to increased demand. The increased demand is thought to be due to increased use of synthetic inhaled cannabinoids laced with anticoagulants.
    • Oral vitamin K is not affected by this shortage.

Available Products

    • Vitamin K injection, Amphastar, 2 mg/mL, 0.5 mL SAF-T-JET prefilled syringe, 10 count, NDC 76329-1240-01
    • Vitamin K injection, Pfizer, 10 mg/mL, 1 mL ampule, 25 count, NDC 00409-9158-01
    • Vitamin K injection, Pfizer, 2 mg/mL, 0.5 mL ampule, 25 count, NDC 00409-9157-01

Estimated Resupply Dates

    • Pfizer has vitamin K injection in 1 mg/mL 0.5 mL ampules and 10 mg/mL 1 mL ampules available.


    • Avoid off-label oral administration of injectable Vitamin K during the shortage.
    • Vitamin K from Amphastar contains polysorbate 80 and propylene glycol.
    • Vitamin K from Hospira contains benzyl alcohol. The product labeling states there is no evidence to suggest toxicity of benzyl alcohol if used as recommended.


Updated July 5, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 29, 2015 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.



Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.